Statement of Principles concerning distal biceps brachii tendinopathy (Reasonable Hypothesis) (No. 3 of 2025)

The instrument establishes a focused set of medical and temporal criteria to operationalise a “reasonable hypothesis” connection between distal biceps brachii tendinopathy (DBBT) and relevant service. The principal concepts in the text are the medical definition of DBBT, the inclusion of death where distal biceps brachii tendinopathy contributed to a terminal event, the enumerated causative or aggravating factors that must be present to raise a reasonable hypothesis, and the requirement that any such factor must be related to the person’s relevant service per the Schedule 1 definition.

Definition of the condition. Section 6(2) defines distal biceps brachii tendinopathy as a clinically symptomatic inflammation or degeneration of the distal biceps brachii tendon. The definition expressly includes partial or complete tendon tears and expressly excludes biciptitoradial bursitis unless accompanied by DBBT. The instrument notes alternate clinical terminology commonly used, such as tendonitis/tendinitis and tendonosis/tendinosis, but the statutory definition is the operative text in subsection 6(2).

Death and terminal events. Section 6(3) expands the condition, for claims purposes, to include death from a terminal event or condition that was contributed to by the person’s DBBT. Schedule 1 defines terminal event by example, listing pneumonia, respiratory failure, cardiac arrest, circulatory failure, and cessation of brain function. The instrument therefore captures situations in which DBBT is one contributing condition to a proximate or ultimate cause of death, provided the contribution is established.

Enumerated factors. Section 8 lists, as minima, the factors which must exist before a reasonable hypothesis is raised:

• sudden forceful extension of the elbow during elbow flexion on the affected side at the time of clinical onset (8(1)); the instrument provides examples such as catching a heavy load with a bent arm, a fall on an outstretched hand, and contact sports in the explanatory note to 8(1);

• performing forceful activities with the hand or forearm on the affected side, combined with either repetitive activities or sustained activities on that side, for at least 1 hour per day, on more days than not, over at least the 4 weeks before clinical onset (8(2)). This factor is precise in quantity and duration;

• abusing anabolic steroids at the time of clinical onset (8(3));

• inability to obtain appropriate clinical management for DBBT before clinical worsening (8(4)).

Service linkage. Section 9 requires that any of the section 8 factors must be related to the person’s relevant service. Schedule 1 defines relevant service expansively across VEA and MRCA categories: operational, peacekeeping, hazardous, British nuclear test defence, warlike, and non‑warlike service (Schedule 1 definitions). Subsection 9(2) specifically circumscribes the operation of factor 8(4): inability to obtain appropriate clinical management is limited to material contribution to, or aggravation of, DBBT where the person’s DBBT was suffered or contracted before or during relevant service but did not arise out of relevant service.

Interaction with other Statements. Section 10 provides a cross‑reference mechanism: if a section 8 factor refers to an injury or disease covered by another Statement determined under subsection 196B(2) of the VEA, then the factors in that other Statement apply as in force from time to time. This creates a layering approach where some causal paths may require applying another Statement’s criteria.

Authority and scope. The Statement is made under subsection 196B(2) VEA (section 3). The instrument states the Authority’s view that there is sound medical‑scientific evidence indicating the condition can be related to relevant service (section 7), which explains why the Statement was promulgated but is not itself a legal determination in individual cases. The instrument operates as a medical determinative aid for claims assessors working under the specified claim provisions (section 4).

These are the principal concepts: a narrowly defined medical condition, inclusion of death where contributory, a discrete and specific list of causative/aggravating factors with quantifiable thresholds, a mandatory service linkage test, and a mechanism to incorporate other Statements. The remainder of this deep dive examines who is affected by these provisions, the duties and rights they create in practice, enforcement mechanics, interactions with other law, and practical compliance.

The instrument binds the Repatriation Medical Authority as maker and is designed to be applied by decision‑makers considering claims under the VEA and MRCA provisions cited in section 4. It directly affects three categories of stakeholders by operation of its role within the claims assessment process: claimants (veterans and former members of the Forces or Peacekeeping Forces), clinicians providing evidence, and administrative decision‑makers within the Department responsible for VEA/MRCA claims. It also has indirect effects on legal advisers, medical assessors engaged in reviews, and insurers or other bodies that might rely on Veterans’ Affairs determinations.

Claimants. The Statement applies to claims to which section 120A of the VEA or section 338 of the MRCA applies (section 4). Those statutory provisions (not reproduced here) are the statutory loci for the “reasonable hypothesis” test; by tying the Statement to those provisions, the instrument affects veterans and other members seeking entitlements where they rely on a reasonable hypothesis linking distal biceps brachii tendinopathy, or death contributed to by it, with relevant service. The effect on claimants is procedural and evidentiary: outcomes of claims turn, in part, on whether the listed factors in section 8 are present and linked to relevant service per section 9.

Clinicians and medical witnesses. The instrument specifies clinical definitions and precise mechanistic factors (for example sudden forceful extension during elbow flexion at the time of clinical onset, section 8(1)). Clinicians providing opinions or reports for claimants or for the department will be required to engage with those terms. They may be asked to opine on timing of clinical onset, whether the activity met the “forceful/repetitive/sustained” threshold in 8(2), whether steroid abuse was present at clinical onset, or whether lack of access to appropriate care materially contributed or aggravated the condition (8(3)-(4); 9(2)). The Statement thus shapes the content clinicians must address to support or oppose a reasonable hypothesis.

Decision‑makers and administrative staff. Those assessing claims will apply the Statement as a test to determine whether the statutory threshold for a reasonable hypothesis is raised. Section 10 further requires decision‑makers to apply other Statements if a factor refers to an injury or disease covered elsewhere, meaning assessors must cross‑check and integrate multiple Statements of Principles where causal links cross conditions. Decision‑makers therefore incur administrative tasks of interpreting clinical material against the exact phrasing in section 8 and verifying the relevant service linkage using the Schedule 1 relevant service definitions.

Indirectly affected parties. Legal advisers, advocates, and medical‑legal experts assisting claimants will tailor evidence collection and submissions to the specific factors and thresholds in the instrument. Rehabilitation providers, employers, and treating hospitals may be solicited for records that establish the timing and nature of activities, availability of clinical management, or documentation of steroid use. The instrument may therefore impose additional evidence‑gathering effort on these parties.

Who does not get affected by the instrument alone. The Statement does not itself create entitlements independent of the VEA/MRCA statutory framework, does not impose criminal or civil liability, and does not on its face create regulatory obligations for private employers. It functions as an administrative evidentiary tool within veterans’ claims processes.

Overall allocation of burdens. The practical burden of proving the presence of a listed factor and its relation to relevant service rests on the claimant assembling supporting evidence. Administratively, the department must assess that evidence against the Statement’s discrete criteria and determine whether the reasonable hypothesis threshold is met. The Schedule’s definitions of relevant service and terminal event constrain the scope of relevant connections to specified categories.

This instrument does not create freestanding statutory duties or civil rights outside the VEA and MRCA framework. Its operative purpose is to provide a determinative medical benchmark for assessing whether a reasonable hypothesis exists linking distal biceps brachii tendinopathy, or death from it, to relevant service. Nevertheless, the instrument imposes practical duties on decision‑makers and sets evidentiary expectations that affect claimants’ rights to prevail on a reasonable hypothesis test.

Duties of decision‑makers. Decision‑makers applying sections 120A (VEA) and 338 (MRCA) will be required to consider the factors set out in section 8 and the service linkage requirement in section 9. Section 10 imposes a duty to apply provisions of other Statements if a section 8 factor refers to an injury or disease covered by another Statement. These are procedural duties within the existing statutory assessment process: the decision‑maker must check whether at least one of the section 8 factors exists and whether the factor is connected to relevant service as defined in Schedule 1.

Duty to interpret definitions as written. The instrument’s Schedule 1 supplies specific definitions which decision‑makers must apply, for example the meaning of distal biceps brachii tendinopathy (see subsection 6(2) cross‑referenced in Schedule 1), relevant service categories (Schedule 1), and terminal event (Schedule 1). Decision‑makers should confine their reasoning to the textual content of the Statement when assessing whether the condition or death falls within the Statement’s scope.

Duty to treat section 8(4) narrowly in relation to service. Subsection 9(2) narrows the application of the inability to obtain appropriate clinical management factor so that it applies only where DBBT was suffered or contracted before or during, but did not arise out of, relevant service, and only to material contribution or aggravation. This limits the duty to consider factor 8(4) to a specific subset of temporal/service histories.

Rights of claimants. Claimants retain the right to have their claims assessed in accordance with the statutory provisions to which this Statement applies. Practically, they have the right to present evidence addressing the enumerated factors, to obtain medical reports that speak directly to the clinical onset and the listed mechanics, and to invoke the Statement in submissions to the decision maker. The Statement effectively prescribes the terms on which a reasonable hypothesis may be established, so claimants have the right to a principled, textually grounded assessment using these criteria.

No penalty or enforcement powers. The instrument does not confer power to impose fines, administrative penalties or criminal sanctions. It does not contain enforcement provisions. Its legal force is confined to shaping the assessment of entitlement claims through the “reasonable hypothesis” standard under the VEA/MRCA provisions referenced in section 4.

Interaction with other Statements. Section 10 creates a duty for decision‑makers to apply other Statements that are relevant to factors in section 8. This means a claimant whose suggested causal pathway crosses into another recognised injury or disease will have that other Statement applied as it stands at the time of assessment, which may expand or contract avenues for establishing a reasonable hypothesis.

Evidentiary implications and presumptions. The Statement itself does not set a legal evidentiary standard of proof; it functions as the Authority’s medical determination of relevant factors. It thereby shapes the fact‑finding exercise. The rights and duties under the underlying statutory scheme, including appeals rights and applicable standards, are determined by the VEA and MRCA provisions and common administrative law; they are not restated in this instrument.

In summary, the key duties are procedural duties of decision‑makers to apply the enumerated factors, definitions, and cross‑references; the practical duty on claimants to adduce evidence addressing these precise terms; and the right of claimants to have the reasonable hypothesis test applied using this Statement. The instrument imposes no separate sanctions or benefit entitlements by its own text.

The Statement contains no provisions that create penalties, fines, offences, or enforcement mechanisms. It is an administrative, medical benchmark document set out under subsection 196B(2) of the VEA (section 3), intended for use in assessing claims under section 120A of the VEA or section 338 of the MRCA (section 4). The instrument therefore functions within the existing statutory claims and review apparatus rather than as a standalone regulatory or penal measure.

What the instrument does not do. It does not prescribe any disciplinary procedure for failure to comply with clinical management. It does not create criminal liability for an individual clinician, treating hospital, or claimant. It does not set administrative fines for failure to produce records or for failing to meet the activity thresholds listed in section 8. The absence of enforcement text means any coercive action or sanction must be grounded in statute outside this instrument, such as other provisions of the VEA, MRCA, or general law.

Practical enforcement consequences for claims. Although the Statement contains no penalties, it has consequential administrative effects in claims processing. If a decision‑maker determines that none of the section 8 factors is present, or that a factor present is not related to relevant service per section 9, the claimant’s attempt to raise a reasonable hypothesis will fail at the administrative stage. That procedural consequence may prevent entitlement being established under the VEA/MRCA pathways that rely on the reasonable hypothesis concept. The instrument therefore operates as a gatekeeping tool, with the practical “enforcement” being acceptance or rejection of a claim on the basis of whether the Statement’s factors are met.

Burden of proof and evidentiary enforcement. The Statement does not state who bears the legal burden of proof for the reasonable hypothesis test, nor does it specify the standard of evidence required. Those matters are governed by the VEA/MRCA provisions and applicable administrative law. In practice, claimants will need to supply evidence sufficient for the decision‑maker to conclude that at least one of the enumerated factors existed and related to relevant service. If evidence is insufficient, the practical consequence is an adverse determination, rather than a statutory penalty.

No special investigatory powers. The Statement does not grant investigatory powers to compel production of medical records, to order examinations, or to require third parties to provide information. Those powers, if they exist, must be sourced in other statutory provisions. The instrument’s effect is limited to guiding medical causation assessment.

Appeal and review. The Statement does not alter appeal rights or review mechanisms. Where a decision based on the Statement is subject to administrative or merits review under the VEA/MRCA framework, normal review routes apply. The document does not itself create or limit appeal routes.

In short, the instrument has no enforcement or penalty clauses. Its effect is administrative and evidentiary: it can cause claims to be upheld or rejected depending on whether its criteria are met, but it imposes no statutory sanctions by its own terms.

This Statement is made expressly under subsection 196B(2) of the Veterans’ Entitlements Act 1986 (VEA) (section 3) and applies to claims to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 (MRCA) applies (section 4). Its interaction with other laws is therefore mediated through those statutory claim mechanisms and through the explicit cross‑reference in section 10 to other Statements of Principles determined under subsection 196B(2) of the VEA.

Primary statutory context. The Statement is a vehicle by which the Repatriation Medical Authority supplies medical determinations intended to be applied to statutory tests located in the VEA and MRCA. The instrument itself does not amend or override the substantive entitlements or procedural provisions in those Acts. It must be read as a medical determinative tool side by side with the relevant provisions of the VEA and MRCA which set out the legal tests for causation, entitlement, and review processes. Any legal effect of the Statement therefore arises only insofar as decision‑makers apply it under the statutory sections identified in section 4.

Cross‑Statement interaction. Section 10 provides that if a section 8 factor refers to an injury or disease covered by another Statement determined under subsection 196B(2), then the factors in that other Statement apply in accordance with its terms as in force from time to time. This creates a hierarchy or networked application: an assessment may require applying multiple Statements where causal factors intersect. Practically, assessors must ensure they are using up‑to‑date versions of all relevant Statements. The instrument therefore interacts with the suite of Statements of Principles produced under the VEA framework.

Definitions with cross‑statutory meaning. Schedule 1 defines “relevant service” by cross‑referencing categories from both the VEA and the MRCA, listing operational, peacekeeping, hazardous, British nuclear test defence, warlike and non‑warlike service. Those definitions align the Statement’s reach with the statutory categories used in the entitlement Acts. The definition of “terminal event” in Schedule 1 intersects with coroner and death certification processes governed by state and territory law; however, the Statement’s terminal event list is specifically for the purposes of whether death was from the condition for claims assessment, not a general modification of state death certification law.

No displacement of other statutory medical standards. The Statement does not state that it displaces or supersedes other statutory medical standards outside the VEA/MRCA framework. For example, workers compensation or private insurance medical standards are not altered by this Statement. If a claimant has concurrent claims under other statutory schemes, each scheme’s medical criteria and statutory processes govern examination of causation for that scheme. The instrument simply establishes the Repatriation Medical Authority’s view of causation for VEA/MRCA claims.

Administrative law and natural justice. The Statement must be applied within the existing decision‑making framework under the VEA and MRCA. That framework is subject to administrative law obligations, including procedural fairness and obligations to take relevant considerations into account. The Statement’s content is evidence for the decision‑maker; it does not negate the need to apply administrative law standards in individual assessments or to provide reasons for determinations that adopt or depart from the Statement’s content.

Evidence rules and medical confidentiality. The Statement contemplates evaluation of clinical onset, history of activities, steroid use and access to treatment. Decision‑making and evidence gathering will therefore interact with privacy laws and rules governing medical records disclosure. The Statement does not modify those laws; disclosure and use of medical records remains subject to applicable privacy and confidentiality regimes.

In brief, the Statement interacts with other laws by operating as an evidentiary tool within the VEA and MRCA claim processes, by requiring cross‑application of other Statements where referenced, and by relying on statutory definitions of relevant service. It does not create standalone statutory obligations beyond its role in the claims assessment context.

The instrument itself records its provenance and dates within the text, but contains no internal history of prior versions or amendments. The front matter identifies the instrument as the Statement of Principles concerning distal biceps brachii tendinopathy (Reasonable Hypothesis) (No. 3 of 2025). The instrument is dated 17 December 2024 (signature block) and the commencement date is 28 January 2025 (section 2). The instrument is made under subsection 196B(2) of the Veterans’ Entitlements Act 1986 (section 3).

No amendments recorded in the text. There are no textual amendments, revocations, or replacement clauses contained within this document. The instrument does not list prior Statements on the same condition. It does not specify that it supersedes any earlier Statement concerning the same condition, nor does it include transitional or savings provisions. The absence of those clauses in the instrument suggests it is a standalone Statement enacted on the dates stated.

Dynamic application via cross‑references. Although there is no internal amendment history, the instrument’s section 10 contemplates dynamism in related Statements: “the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.” This means the effective application of section 8 factors that refer to other injuries or diseases may change over time if those other Statements are amended. The Amendment History for those other Statements will therefore indirectly affect application of this Statement when cross‑references exist.

External amendment mechanism. Any amendment to this Statement must be made by the Repatriation Medical Authority using the same statutory power, subsection 196B(2) of the VEA. The instrument does not state any limits on amendment, nor any special consultation or review process within the text. Changes to the Statement will be reflected by later instruments signed by the Authority and published in the usual channels, but no timeline or history is supplied here.

Consequences for practitioners. Because the Statement can be updated in other Statements that it cross‑references, practitioners must monitor both this Statement and any other implicated Statements for amendments. The instrument itself gives no schedule for review or expiry; the commencement date is fixed and future amendments would need to be promulgated independently.

Summary. The instrument contains a single enactment date and signature date, no in‑text amendment history or transitional rules, and an explicit mechanism that allows related Statements to be applied as they change. Any detailed amendment history must be obtained from the official legislative instrument register or the Repatriation Medical Authority’s publications; the document supplied contains no retrospective amendments or prior versions.

The instrument does not record any litigation history. It is a Statement of Principles produced by the Repatriation Medical Authority under subsection 196B(2) of the Veterans’ Entitlements Act 1986 (section 3), and the text contains no references to judicial decisions, appeals, or previous court considerations of this particular Statement. There are no internal citations to case law, no references to past determinations, and no record of challenges or adjudications within the instrument itself.

Where litigation might arise. Although the instrument contains no litigation history, it will operate within a statutory claims framework that is subject to administrative and judicial review in appropriate circumstances. Decisions that apply this Statement may be challenged through the statutory appeal routes and administrative law remedies available under the VEA, MRCA and related administrative law regimes. For example, an adverse decision by a department decision‑maker that relies on the Statement could be subject to merits review or judicial review processes. The instrument itself does not alter rights of review; however, the absence of litigation history in the document means practitioners must rely on external case law databases and the decisions of tribunals and courts to identify precedential litigation addressing similar Statements or the interpretation of “reasonable hypothesis” under the relevant statutory sections.

What to expect in review proceedings. If a decision is appealed where the Statement is engaged, review bodies will typically examine whether the decision‑maker applied the Statement correctly, whether they considered all relevant evidence, and whether procedural fairness was observed. The Statement’s precise language, particularly the quantified activity threshold in section 8(2) and the temporal limitation in subsection 9(2), may be focal points in litigation, but this instrument provides no examples of how courts or tribunals have treated those phrases.

No named cases or authorities in the text. The instrument does not list or cite any cases, and it contains no footnotes or references to judicial pronouncements. Any litigation history involving this Statement, or judicial treatment of comparable Statements, must be sourced externally from tribunal or court records. The document as provided is silent on previous challenges or judicial interpretation.

In short, there is no litigation history recorded in this Statement. Practitioners should anticipate that disputes about application will proceed through the statutory review and appeal channels available under the VEA and MRCA, but should consult external legal databases for decisions that interpret similar Statements of Principles or the concept of “reasonable hypothesis.”

This Statement contains several precise drafting choices and limitations that have material consequences for claimants, clinicians and decision‑makers. These are factual "gotchas" that can determine whether a reasonable hypothesis is found, and therefore should be checked closely in any claim strategy.

Narrow medical definition and an explicit exclusion. Subsection 6(2) defines distal biceps brachii tendinopathy as clinically symptomatic inflammation or degeneration of the distal biceps brachii tendon and includes partial or complete tears. It explicitly excludes biciptitoradial bursitis unless it is accompanied by distal biceps brachii tendinopathy. If a medical record documents biciptitoradial bursitis without clear evidence of DBBT, the Statement will not assist the claimant.

Timing and “time of clinical onset.” The factor in section 8(1) requires a sudden forceful extension of the elbow during elbow flexion on the affected side at the time of clinical onset. Claims will hinge on precise timing: clinicians must state when “clinical onset” occurred and whether the described forceful mechanism coincided. Ambiguous or retrospective descriptions of onset may be insufficient to satisfy 8(1).

Quantified activity threshold in section 8(2). Section 8(2) is specific: forceful activities with the hand or forearm on the affected side, combined with repetitive or sustained activities, for at least 1 hour per day, on more days than not, over a period of at least the 4 weeks before clinical onset. The quantifiers “at least 1 hour per day,” “on more days than not,” and “at least the 4 weeks” are strict thresholds. Vague statements that someone performed repetitive work “most days” without records or contemporaneous logs risk failing this criterion. Decision‑makers will likely require clear evidence to meet the precise durations.

Anabolic steroid abuse. Section 8(3) links steroid abuse at the time of clinical onset with DBBT. The term used is “abusing anabolic steroids,” which carries clinical and factual meanings. Evidence of prescription, supervised therapeutic steroid use, or remote past use will need to be distinguished from “abuse at the time of clinical onset.” Lack of contemporaneous documentation of non‑medical anabolic steroid use is a potential evidential gap.

Access to clinical management limited in scope. Section 8(4) covers inability to obtain appropriate clinical management for DBBT before clinical worsening. Subsection 9(2) narrows this further: it applies only where the person’s DBBT was suffered or contracted before or during, but did not arise out of, relevant service, and then only where inability to obtain appropriate management materially contributed to or aggravated the condition. In short, 8(4) cannot be used to bootstrap causation where DBBT arose out of service; it only applies when DBBT pre‑existed or was contracted before/during service but not caused by it. Claimants whose DBBT first arose during service and is alleged to have been worsened by lack of care may not be able to rely on 8(4) if the condition arose out of service.

Service linkage requirement. Section 9(1) requires that any factor in section 8 must be related to the person’s relevant service. The Schedule’s definition of relevant service includes categories across the VEA and MRCA, but the instrument imposes a temporal and causal nexus. Evidence must connect the listed factor to the person’s activities during the relevant service category. For example, a forceful activity occurring during civilian employment will not be related to relevant service unless linked temporally and causally to the period defined as relevant service.

Cross‑reference complexity. Section 10 requires that if a section 8 factor refers to an injury or disease covered by another Statement, the other Statement's factors apply as in force from time to time. Practically, this can create unexpected evidentiary layers: a factor that appears straightforward may trigger application of another Statement with its own stringent thresholds, changing the assessment calculus.

“Death” includes common terminal events. Schedule 1 defines “terminal event” by example, including pneumonia and cardiac arrest. A death where DBBT is only a minor or indirect contributor to a listed terminal event will require clear causal linkage; mere presence of DBBT in medical history will not suffice. Decision‑makers must be shown how DBBT contributed to the proximate or ultimate cause of death.

No guidance on standard of proof. The Statement does not specify the standard of proof or the adjudicative process. Practitioners should not assume that satisfying a factor in section 8 guarantees acceptance; the underlying statutory provisions and administrative law requirements still govern the decision‑maker’s overall assessment.

No express record‑production powers. The Statement does not modify disclosure powers. If crucial supporting evidence is held by third parties, claimants must rely on ordinary records‑gathering routes rather than any compulsion created by the Statement.

In sum, the drafting contains tight temporal and quantitative tests, narrow exclusions, and a specific treatment of inability to obtain care which is itself temporally limited. These features create several points where evidentiary shortcomings or imprecise clinical statements can lead to rejection of a claim relying on a reasonable hypothesis. Practitioners should align evidence collection precisely to the instrument’s language.

For claimants, clinicians, and decision‑makers working with claims involving distal biceps brachii tendinopathy under the VEA/MRCA reasonable hypothesis provisions, compliance means assembling and presenting evidence that directly maps to the instrument’s defined terms and thresholds. Below are practical steps, rooted in the Statement’s text, for aligning evidence and submissions to the factors and definitions.

1. Map the condition to the instrument’s definition (subsection 6(2)).

   • Ensure medical reports state that the person has clinically symptomatic inflammation or degeneration of the distal biceps brachii tendon, or a partial or complete tear. Explicitly reference the distal biceps brachii tendon.
   • If biciptitoradial bursitis is present, clinicians should state whether it is accompanied by DBBT, because bursitis alone is excluded.

2. Establish the time of clinical onset and mechanism where relying on 8(1).

   • Obtain contemporaneous clinical notes, emergency department records, or treating clinician statements that fix the time of clinical onset.
   • Clinician’s opinion should describe whether a sudden forceful extension of the elbow occurred during elbow flexion on the affected side at the time of onset. Examples in the instrument include catching a heavy load with a bent arm, a fall on an outstretched hand, or contact sports; where applicable, link the claimant’s activity to those examples (section 8(1) and its note).

3. If relying on section 8(2) (forceful plus repetitive or sustained activity), document quantity and duration precisely.

   • Produce employment records, duty statements, rosters, shift logs, or contemporaneous diaries showing the required intensity: at least 1 hour per day, on more days than not, over at least the 4 weeks before clinical onset.
   • Have treating or occupational physicians quantify the nature of the activities as “forceful” and as “repetitive” or “sustained” with reference to clinical standards used in the report.

4. If alleging anabolic steroid abuse under section 8(3), produce clear evidence of non‑prescribed steroid use at the time of clinical onset.

   • Medical or pharmacy records that document anabolic steroid prescriptions should be distinguished from evidence of abuse. Where steroid abuse is alleged, contemporaneous clinical notes, toxicology reports, or credible admissions recorded in clinical notes will be necessary.

5. If relying on inability to obtain appropriate clinical management (8(4)), satisfy the temporal and causal constraints in subsection 9(2).

   • Demonstrate that DBBT was suffered or contracted before or during relevant service but did not arise out of relevant service. Provide medical records establishing onset prior to or during service.
   • Evidence of inability to obtain care should include appointment attempts, referrals, waitlists, denial letters, or correspondence with treating providers showing lack of access before clinical worsening. Clinician opinion should address whether lack of timely appropriate management materially contributed to or aggravated the condition.

6. Link any asserted factor to relevant service (section 9(1) and Schedule 1).

   • Establish that the activity or lack of management occurred during a period that fits the Schedule 1 definition of relevant service (operational, peacekeeping, hazardous, British nuclear test defence, warlike, or non‑warlike as listed). Provide service records, deployment histories, and any contemporaneous incident reports that locate the activity temporally and contextually within the claimant’s relevant service.

7. When a section 8 factor refers to another Statement, incorporate that Statement’s requirements (section 10).

   • Identify any cross‑referenced condition and procure the current version of the other Statement of Principles. Ensure evidence satisfies both this Statement’s factor and the other Statement’s relevant factors.

8. Prepare clinicians to address the Statement’s precise language.

   • Clinical opinions should adopt the Statement’s phrasing where possible, for example addressing “sudden forceful extension…during elbow flexion” or quantifying “at least 1 hour per day” rather than using more general terms. This reduces interpretive gaps in assessment.

9. Document death causation carefully where death is claimed as resulting from DBBT.

   • Provide death certificates, coroner reports, and treating clinicians’ opinions explaining how DBBT contributed to the terminal event listed in Schedule 1 (for example, explain mechanistically how DBBT contributed to pneumonia, respiratory failure, or circulatory failure). Address proximate and ultimate causation.

10. Anticipate and fill evidentiary gaps.

    • Because the Statement itself provides no power to compel records, obtain necessary documents proactively from employers, military units, treating hospitals, and physicians. If records are missing, prepare affidavits, witness statements, or contemporaneous witness attestations that address the precise criteria.

11. For decision‑makers: document reasoning against the Statement’s phrasing.

    • Decisions should record which section 8 factor was considered, how the evidence matches or fails the precise wording, whether the relevant service linkage under section 9 is established, and whether any cross‑referred Statement under section 10 was applied. This supports transparency and reviewability.

12. Maintain currency with Statements.

    • Because section 10 applies other Statements “as in force from time to time,” practitioners and decision‑makers must check for updated Statements that might change the causal criteria applicable to any cross‑referenced factor.

Practical record checklist. For a claim relying on this Statement, assemble: clinical records (onset and diagnosis), medical imaging/reports (if tears are alleged), military service records, incident/accident reports, employment/duty logs showing activity levels, appointment/referral/waitlist documentation regarding access to care, toxicology or clinician notes regarding steroid use, and contemporaneous witness statements describing forceful events.

In short, compliance means translating the Statement’s precise, sometimes quantified language into documentary evidence and clinician opinions that correspond directly to the enumerated factors and the Schedule 1 definitions. Doing so reduces risk that an assessment will find those thresholds unmet on purely evidential grounds.